MUSK and myasthenia gravis: Intravenous RTX was recommended in refractory MG.40 One clinical controlled trial demonstrated the probability of favorable outcomes increases with a significant steroid‐sparing effect in anti‐MuSK antibody‐positive MG patients.45 A meta‐analysis of RTX concluded the overall effective rate was 83.9%, and incidence of AEs was rather low.7